Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
klh-pulsed autologous dendritic cell vaccine (Leo W. Jenkins Cancer Center)
- Development stage
- Discontinued
- Lead developer
- Leo W. Jenkins Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intratumoral
01
Overview
KLH-pulsed autologous dendritic cell vaccine is an investigational cellular immunotherapy developed by the Leo W. Jenkins Cancer Center. It consists of a patient's own dendritic cells that have been pulsed with keyhole limpet hemocyanin (KLH), a highly immunogenic carrier protein. The vaccine is designed to be administered via direct intratumoral injection, typically following treatments like radiation or gene therapy (e.g., TNFerade) that induce tumor cell apoptosis. This process is intended to allow the dendritic cells to capture released tumor antigens and present them to the immune system, with KLH serving as a potent adjuvant to prime and activate a systemic, T-cell-mediated anti-tumor response. A Phase II clinical trial evaluating this vaccine in patients with unresectable or metastatic pancreatic cancer was terminated due to poor recruitment.
- Other names
- KLH-pulsed autologous dendritic cellsKLH-pulsed DC vaccine
02
Targets
ATL-TAA (Tumor-associated antigens (TAA) contained in autologous tumor lysate (ATL))
Beyond the preview
Go deeper on klh-pulsed autologous dendritic cell vaccine (Leo W. Jenkins Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on klh-pulsed autologous dendritic cell vaccine (Leo W. Jenkins Cancer Center).